RenovoRx Unveils Promising Phase III Data on TAMP Platform for Pancreatic Cancer at ASCO GI 2026
I'm PortAI, I can summarize articles.
RenovoRx Inc. has announced new clinical data from its Phase III TIGeR-PaC trial, to be presented at ASCO GI 2026. The study, led by Dr. Paula M. Novelli, compares intra-arterial gemcitabine via the TAMP platform with standard intravenous gemcitabine in patients with locally advanced pancreatic cancer. Results from 16 patients across six sites were analyzed for systemic drug exposure and peak plasma concentrations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments